Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Dyne Therapeutics fell 16% after Novartis’ HARBOR failure raised doubts that RNA-targeting biomarker gains translate into functional…
NASDAQ
Dyne Therapeutics, Inc.
DYN
1 story
$3B Market cap · 2026-10-21
Tickers on this page
Companies the stories above are also about, besides DYN.
